Publication Cover
Natural Product Research
Formerly Natural Product Letters
Volume 38, 2024 - Issue 11
108
Views
0
CrossRef citations to date
0
Altmetric
Research Article

The sesquiterpenes with the COVID-19 Mpro inhibitory activity from the Carpesium abrotanoides L.

, , , , , , , & show all
Pages 1909-1917 | Received 01 Mar 2023, Accepted 23 Jun 2023, Published online: 05 Jul 2023
 

Abstract

The extract of the whole plant of Carpesium abrotanoides L. yielded four new sesquiterpenes including a novel skeleton (claroguaiane A, 1), two guaianolides (claroguaianes B–C, 2–3), and one eudesmanolide (claroeudesmane A, 4), together with three known sesquiterpenoids (5–7). The structures of the new compounds were elucidated by spectroscopic analysis especially 1D and 2D NMR spectroscopy and HRESIMS data. Additionally, all the isolated compounds were preliminarily evaluated for the inhibitive activity of COVID-19 Mpro. As a result, compound 5 showed moderate activity with an IC50 value of 36.81 μM and compound 6 exhibited a potent inhibitory effect with an IC50 value of 16.58 µM, while other compounds were devoid of noticeable activity (IC50 > 50 μM).

Graphical Abstract

Acknowledgements

We sincerely thank the ‘Cultivation project of Dongguan Institute of Guangzhou University of Chinese Medicine’.

Disclosure statement

No potential conflict of interest was reported by the author(s).

Additional information

Funding

The author(s) reported there is no funding associated with the work featured in this article.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.